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Abstract: Transplantation of adult human hepatic stem/progenitor cells (hHSPCs) has been considered as an al-
ternative therapy, replacing donor liver transplantation to treat liver cirrhosis. This study assessed the antifibrotic 
effects of hHSPCs in mice with fibrosis induced by carbon tetrachloride (CCl4) and examined the actions of hHSPCs 
on the fibrogenic activity of human hepatic stellate cells (HSCs) in a coculture system. Isolated hHSPCs expressed 
stem/progenitor cell phenotypic markers. Mice were given CCl4 (twice weekly for 7 weeks) and hHSPC transplanta-
tion weekly. CCl4 induced advanced fibrosis (bridging fibrosis and cirrhosis) in mice, which was prevented by hHSPC 
transplantation. The liver of hHSPC-transplanted mice showed only occasional short septa and focal parenchymal 
fibrosis, and a 50% reduction in hepatic collagen, assessed by Sirius red stain histomorphometry. Moreover, the pro-
teins for α-smooth muscle actin (α-SMA) and collagen I were decreased. While α-SMA, collagen α1(I), and tissue in-
hibitor of metalloproproteinase-1 mRNAs were decreased, matrix metalloproteinase (MMP)-1 mRNA was increased, 
consistent with decreased fibrogenesis. MMP-2 and transforming growth factor-β were not affected. Alanine ami-
notransferase and aspartate aminotransferase were lower, suggesting improvement of liver function/damage. In 
coculture, hHSPCs elicited changes of α-SMA and fibrogenic molecules in HSCs similar to those observed in vivo, 
providing evidence for a functional link between hHSPCs and HSCs. A decreased HSC proliferation was noted. Thus, 
transplantation of hHSPCs prevents histogenesis of advanced liver fibrosis caused by CCl4. hHSPCs mediate down-
regulation of HSC activation coincident with modulation of fibrogenic molecule expression, leading to suppression 
of fibrogenesis both in vivo and in vitro. 
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Introduction
Hepatic fibrosis is a chronic liver disease that 
results from wound healing in response to liver 
injury. The fibrosis will progress to cirrhosis, the 
end stage of liver fibrotic disease. Cirrhosis 
affects hundreds of millions of people world-
wide and causes over 1 million deaths annually 
[1]. In the US, there are 17000 adults and chil-
dren awaiting liver transplantation (Data from 
American Liver Foundation). Every year more 
than 1500 people die waiting for a donor liver 
to become available. Currently, orthotopic liver 
transplantation is the only treatment that im- 
proves the survival rate in patients with live cir-
rhosis [2, 3]. Unfortunately, the availability of 
liver transplantation is limited due to the short-
age of donor livers, serious complications, im- 
munological suppression and high costs. The- 
refore, searching for an effective alternative 
treatment for advanced liver fibrosis is essen-
tial. Cell therapy using hepatocyte transplanta-
tion presents a promising alternative to donor 
liver transplant in patients with metabolic dis-
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eases as well as acute and chronic liver failure 
[3, 4]. However, the supply of viable hepato-
cytes is limited by the shortage of liver donors 
and their low proliferative rate both in vitro and 
in vivo [3, 5]. Because of their great capacity to 
proliferate and ability to differentiate into ma- 
ture hepatocytes, human hepatic stem/progen-
itor cells (hHSPCs) from adult liver [6] that 
reside in the canals of Hering [7] may have 
potential therapeutic effects against end-stage 
liver cirrhosis. 
Accordingly, in the present study we undertook 
to assess the antifibrotic effects of adult 
hHSPCs in experimental fibrosis in vivo and in 
vitro. We first assessed the effects of hHSPC 
transplantation on the histogenesis of ad- 
vanced fibrosis, including bridging fibrosis and 
cirrhosis, in the carbon tetrachloride (CCl4) 
mouse model of fibrosis, and then examined 
the actions of hHSPCs on the fibrogenic activity 
of hepatic stellate cells (HSCs)-the principal 
extracellular matrix producing of the liver [8] in 
a co-culture system. The ultimate goal is to 
establish a preclinical model of adult hHSPC 
transplantation therapy for hepatic fibrosis that 
could be translated into clinical medicine.
Materials and methods
Induction of hepatic fibrosis in mice by CCI4
Male C57BL6 mice weighing 22-25 g (pur-
chased from Beijing Weitong Lihua Company, 
China) were maintained according to National 
Institute of Health guidelines for the care and 
use of animals, approved by the Institutional 
Animal Care and Use Committee of Jining 
Medical University Affiliated Hospital. Mice we- 
re kept in the Animal Care Facility of Jining 
Medical University with a 12-h light-dark cycle 
at constant temperature. Mice had free access 
to tap water during the study period. Mice were 
divided into 2 groups with 10 per group. They 
were administered CCl4 intraperitoneally (IP) at 
a dose of 0.3 ml/kg in olive oil twice a week for 
7 weeks. For cell transplantation, the CCl4-mice 
were given IP either phosphate buffer saline 
(PBS) or 2 × 106 hHSPCs (infra vide), weekly for 
7 weeks. The mice tolerated the treatments 
well and no overt adverse effects were ob- 
served. At the time of sacrifice, blood was col-
lected in EDTA containing microfuge tubes and 
pelleted at 5,000 rpm for 10 min. Serum sam-
ples were obtained for alanine aminotrans- 
ferase (ALT) and aspartate aminotransferase 
(AST) measurement. Liver was removed and 
divided into portions as follows: formalin fixa-
tion for Sirius red staining for collagens; snap 
frozen in liquid nitrogen for mRNA extraction; 
and homogenization in protein buffer for pro-
tein analysis by Western blotting.
Sirius red stain for collagens and histomor-
phometry of hepatic fibrosis
Liver tissue was fixed in 10% formalin, embed-
ded in paraffin and sectioned according to the 
standard methods. The sections were stained 
for collagens-histological marker of fibrosis-
with 0.1% Sirius red and 0.01% fast green in 
saturated picric acid (Sigma-Aldrich, St. Louis, 
MO, USA). Three Sirius red-stained sections 
from each mouse were used for histological 
evaluation of fibrosis. In each section, six imag-
es of the liver lobules were taken at a magnifi-
cation of × 100, providing a total of 18 images 
per animal. These were used for collagen quan-
tification by histomorphometry using a comput-
erized Bioquant Life Science® morphometry 
system. 
Isolation of human HSCs
Wedge sections of normal human live in select-
ed patients undergoing hepatic resection for 
primary benign tumors or for a single metas- 
tasis from colon cancer were used as a sour- 
ce of HSCs. Cells were isolated as a previously 
described [9]. Immediately after hepatectomy, 
a piece of liver tissue was placed in Dulbecco’s 
modified Eagle’s medium (DMEM; Invitrogen, 
Carlsbad, CA, USA). The liver was washed and 
an intrahepatic vein cannulated for in situ 
digestion with collagenase B and pronase (Ro- 
che Applied Science, Indianapolis, IN, USA). The 
digested liver was subject to density gradient 
centrifugation to separate the HSC fraction. 
The cells were collected and plated on a plas- 
tic dish for culturing, designated as primary 
human HSCs. The protocol was approved by 
the Human Ethics Committee at Jining Medical 
University Affiliated Hospital. Informed cons- 
ents were obtained from the guardians.
Isolation and culture of hHSPCs
Isolation of hHSPCs was performed as follows: 
Human liver specimens (20 to 50 g) which was 
obtained from Jining Medical University Affi- 
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liated Hospital were first perfused in situ for 10 
minutes with 200 to 300 mL of EGTA buffer and 
collagenase type IV (0.05%) in DMEM until the 
tissue became soft and showed signs of disso-
lution. The tissue was minced and the cell sus-
pension was centrifuged twice at 50 × g for 2 
min at 4°C. The supernatant was collected and 
centrifuged at 150 × g for 8 min at 4°C. The 
resultant cell pellet was resuspended in DMEM 
and centrifuged at 150 × g for 5 min at 4°C. 
Finally, the pelleted cells containing crude 
hHSPCs were suspended in PBS for purifica- 
tion in density gradients made of 50% Percoll 
(Sigma-Aldrich), 20% Percoll and cell suspen-
sion. The preparation was centrifuged at 350 × 
g for 20 min at 4°C. The interface between the 
20% and 50% Percoll was decanted to a tube 
and centrifuged at 350 × g for 5 min. The puri-
fied hHSPCs were collected and used for cul-
ture in 6-well plates in DMEM supplemented 
with 10% FBS, 100 U/ml penicillin and 100 
μg/ml streptomycin. These were cultured for 
2-3 weeks with the medium changed twice a 
week. When colonies became visible, they were 
encircled with cloning rings and subcultured 
to an individual well of a 6-well plate. The ex- 
panded cells were taken for assessment of 
markers of hepatic stem cells. Thereafter, cells 
were transferred to T-75 flasks. At confluence, 
cells were taken for experiments. 
Co-culture of hHSPCs and human HSCs
This was performed in 6-wells plates with tran-
swell inserts containing microporous mem-
brane (3 μm pore; Falcon, Becton Dickinson, 
NJ, USA). Primary human HSCs (50,000 cells/
well) were seeded into the wells of the plates 
(lower compartments), while hHSPCs were se- 
eded into the transwell inserts (upper compart-
ments) at either 16,000 cells or 150,000 cells 
in a 1/3 or 3/1 proportion relative to HSCs, 
respectively. hHSPCs and HSCs were co-incu-
bated at 37°C in a 5% CO2-air humidified at- 
mosphere. For controls, HEK-293 cells (human 
embryonic kidney cells) were used in place of 
hHSPCs in the co-culture protocol. The experi-
ments were conducted in triplicates. After co-
cultured for 24 hr and 48 hr, HSCs were taken 
for qRT-PCR (quantitative Real Time-Polyme- 
rase Chain Reaction), Western blot analyses 
and cell proliferation measurement.
RT-PCR
Total RNA was extracted from 50 mg of the 
mouse liver and primary human HSCs that had 
been co-cultured with hHSPCs as described 
above. The RNAs were purified using an RNeasy 
Mini kit (Qiagen, Valencia, CA, USA). RNA (3 µg) 
was reverse transcribed into cDNA using Spr- 
intTM RT Complete-RNA to cDNA EcoDryTM 
Premix (Double Primed) tubes (Clontech, Mo- 
untain View, CA, USA) and analyzed in triplicate 
by qRT-PCR using SYBR green qPCR Master 
Mix (Roche Applied Science) on the LightCycler 
480 Real-Time PCR System (Roche Applied). 
Data are presented as the relative expression 
of fibrogenic genes after normalized to GAP- 
DH. The sequences for the primers are listed in 
Table 1. 
Table 1. SYBR Green Real-Time Quantitative PCR Primer Sequences
Target gene Forward primer Reverse primer
TGF-β 5’-CAAGGGCTACCATGCCAACT-3’ 5’-AGGGCCAGGACCTTGCTG-3’
α-SMA 5’-GTCCCAGACATCAGGGAGTAA-3’ 5’-CAGCACCGCCTGGATAGCC-3’
Collagen Iα1 5’-GGCTTCCCTGGTCTTCCTGG-3’ 5’-CCAGGGGGTCCAGCCAAT-3’
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Western blot
Proteins from the mouse liver and co-cultured 
human primary HSCs cells were homogenized 
and extracted using RIPA lysis buffer (50 mM 
Tris-HCl, pH = 8, 150 mM NaCl, 1% NP-40, 
0.5% sodium deoxycholate and 0.1% SDS) con-
taining protease and protein phosphatase in- 
hibitor mixtures (Roche Applied Science). The 
protein concentration was determined with a 
Bio-Rad DC kit (Bio-Rad, Hercules, CA, USA). 
Antibodies used were as follows: rabbit anti-
collagen type I (1:3,000) (Rockland Immuno- 
chemicals, Gilbertsville, PA, USA), mouse anti-
alpha-smooth muscle actin (αSMA) (1:500) 
(Millipore, Boston, MA, USA), and rabbit anti-
GAPDH (1:2,000) (Santa Cruz, Santas Cruz, CA, 
USA).
Densitometric analysis
Enhanced chemiluminescent images on the 
immunoblots were analyzed by scanning densi-
tometry and quantified with a BIOQUANT NOVA 
imaging system. All values were normalized to 
housekeeping protein and expressed as fold 
changes relative to the controls. 
Cell proliferation assay
HSC cell proliferation was determined by incor-
poration of [3H]-thymidine into DNA as previ-
lized in 0.25% sodium hydroxide/0.25% sodium 
dodecyl sulfate. After neutralization with hydro-
chloric acid (1N), the radioactivity was mea-
sured in a liquid scintillation counter (Be- 
ckman Coulter).
Statistics 
Results are expressed as means ± standard 
deviation. Statistical significance between gro- 
ups was tested using an unpaired Student’s 




In culture, hHSPCs that were attached on cul-
ture plates appeared small and round, forming 
colonies at about first 15 days (Figure 1A). In 
subculture, the cells looked enlarged and more 
flattened, resembling hepatocytes (Figure 1B). 
These hHSPCs were found to express both 
CK19 (biliary epithelial cell marker) and albu-
min (hepatocyte lineage marker), as disclosed 
by Western blotting in Figure 1C. Exposure of 
the hHSPCs culture to 20 ng/ml hepatic growth 
factor (HGF) for 5 days, followed by treatment 
with 1.5% dimethyl sulfoxide (DMSO) in 10% 
fetal bovine serum (FBS) supplemented DMEM 
Figure 1. Phase contrast microscopy (A, B) and expression of hepatocyte 
and biliary epithelial cell markers (C, D) of hHSPCs. (A) During the first 10-20 
days in culture, the cells that are attached on the dish occur in cluster and 
appear round. (B) In subculture, the cells are spreading and look flattened 
and larger. Original magnification 100 ×. (C) Western blots demonstrate ex-
pression of albumin and CK19 by hHSPCs. Upon exposure to DMSO and 
HGF, albumin expression is elevated while CK19 expression is lost. (D) RT-
PCR shows that hHSPCs express the hepatocyte marker genes Albumin, CK8 
and weakly AFP, as well as the cholangiocyte marker genes CK7 and CK19.
ously described [9]. hHSPCs 
or HEK 293 cells (as control) 
were seeded into the upper 
compartments of the tran-
swell inserts (upper compart-
ments) and primary human 
HSCs were plated (20,000 
cells per well) in the lower 
compartments of 24-wells 
plates. hHSPCs or HEK 293 
cells were co-incubated with 
HSCs at 1:3 and 3:1 propor-
tions for 24 and 48 hours. 
Then, 1 μCi/mL 3H-thymidine 
(specific activity 6.7 Ci/mmo- 
le; PerkinElmer, Waltham, MA, 
USA) was added to the HSC 
culture and incubated for ad- 
ditional 12 hours before har-
vesting. HSCs were washed 
three times with ice-cold PBS 
and fixed in methanol for 30 
min at 4°C. Cells were solubi-
Adult human hepatic stem/progenitor cells and hepatic fibrosis
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for an additional 5 days resulted in a loss of 
CK19 expression, concomitant with an en- 
hancement of albumin expression. These data 
indicate differentiation of hHSPCs into hepato-
cyte-like cells in response to HGF and DMSO. 
Additionally, RT-PCR analysis revealed that 
hHSPCs strongly expressed hepatocyte marker 
genes ALB and CK8, while weakly expressed 
the gene for AFP. The cholangiocyte marker 
genes CK7 and CK19 were also expressed at a 
high level in hHSPCs (Figure 1D).
Anti-fibrotic effects of hHSPCs on hepatic fibro-
sis induced by CCI4 in mice
As revealed by Sirius red staining for collagens, 
the livers of CCl4-mice receiving PBS vehicle 
developed advanced fibrotic changes showing 
bridging fibrous septa (bridging fibrosis), incom-
plete nodule formation, and complete nodule 
formation (cirrhosis)-histological hallmarks of 
advanced fibrosis (Figure 2A). In striking con-
trast, no bridging septa and nodule formation 
were observed in the livers of the CCl4-mice 
receiving hHSPC transplantation. In some of 
these livers, there were occasional short septa 
and focal parenchymal fibrosis present in the 
liver lobules. Histomorphometry revealed that 
the percent of Sirius red-stained collagen area 
in the lobules was reduced by more than 50% 
in the CCl4-mice with hHSPC transplantation 
(Figure 2B).
Having demonstrated the beneficial effect of 
hHSPC transplantation against the develop-
ment of advanced fibrosis induced by CCl4, we 
examined expression of fibrogenic molecules in 
the mouse liver. As shown in Figure 3A, 3B, the 
protein content for α-SMA or collagen I was sig-
nificantly decreased (40%) by hHSPCs trans-
plantation into the CCl4-mice. Furthermore, the 
mRNA levels for αSMA, collagen α1(I), and tis-
sue inhibitor of metalloproteinase-1 (TIMP-1) 
were significantly decreased (35%, respective-
ly) in CCl4-mice received the hHSPCs transplan-
tation, while the mRNA for matrix metallopro-
teinase (MMP)-13 was increased by 40% (Fi- 
gure 3C). The mRNAs for TGFβ1 and MMP-2, 
however, were not affected.
hSCPCs transplantation corrected the CCl4-
induced liver damage 
Liver functions of mice were evaluated by mea-
surement of plasma ALT and AST. Mice with 
CCl4 plus hHSPCs transplantation had signifi-
cantly lower ALT (320.6 ± 62.2 U/dl; P < 0.05, N 
= 10) and slightly lower AST (295.3 ± 135.2 U/
dl) activity compared to those of mice treated 
with CCl4 alone (ALT, 512.6 ± 92.3 U/dl and 
AST, 503.3 ± 61.2 U/dl). These data indicate 
the beneficial effect of hHSPCs transplantation 
in correcting liver damage/adverse liver func-
tions caused by CCl4.
Effects of hHSPCs on human primary HSCs in 
co-culture
To test the antifibrotic actions of hHSPCs on 
primary human HSCs in co-culture, we deter-
mined expression of fibrosis-related molecules 
in HSCs. Figure 4A, 4B shows that hHSPCs 
significantly decreased the protein levels for 
Figure 2. A: Liver fibrosis revealed by Sirius red staining for collagens. Top row: Representative images showing the 
development of advanced fibrosis induced by CCl4, which includes formation of nodules (cirrhosis) and linking septa 
without apparent nodular formation (bridging fibrosis). Bottom row: Representative images showing fibrosis in mice 
treated with CCl4 and were also given hHSPCs. Short septa and focal fibrotic tissue are visible. Original magnification 
100 ×. B: Histomorphometry of Sirius red stained collagens. The amount of collagens in the liver parenchyma was 
halved in mice received the hHSPC transplantation. N = 10 mice/group.
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αSMA (60%) and collagen I (50%) in HSCs. 
Additionally, hHSPCs suppressed the mRNA 
levels for αSMA, α1(I) collagen, and TIMP-1, 
each by 30%, in human HSCs, while elevated 
mRNA for MMP-1 by 23% (Figure 4C). The gene 
expression for TGFβ1 and MMP-2 was not 
affected.
Figure 5 shows inhibition of primary HSC pro- 
liferation by hHSPC in the co-culture system 
by more than 25% at the ratio of 3:1 for 
hHSPCs:HSCs for 24 h, but not at the 1/3 ra- 
tio, suggesting a dose response. Also, the inhi-
bition of proliferation seems to be transient as 
the effect disappeared in cells co-cultured for a 
longer duration of 48 hr.
Discussion
Experimental cell-based therapy for liver fibro-
sis and/or liver failure has been examined 
using stem cells from extrahepatic sources or 
from fetal and adult livers [3, 10]. Specifical- 
ly, mesenchymal stem cells derived from 
Transplantation of human fetal hepatic progeni-
tor cells to a cohort of 25 patients with end-
stage decompensated cirrhosis demonstrated 
a decrease in the Mayo’s Model for End Stage 
Liver Disease (MELD) mean score in 6 months 
follow-up [15]. Along this line, fetal liver stem 
cells were found to contribute to the recovery of 
fulminant hepatic failure in rats [16]. 
Adult human hepatic stem cells were reported 
to contribute to the regeneration of liver paren-
chyma in severe-combined immunodeficient 
mice [17]. Additionally, the stem cells improv- 
ed liver injury in a mouse model of fulminant 
liver failure, accompanied by reduction in ani-
mal mortality, decrease in apoptosis and en- 
hancement of liver regeneration [18]. 
It is noteworthy that the above mentioned stud-
ies were aimed at the reduction of either estab-
lished cirrhosis or chronic liver injury/failure in 
animal models, or treatment of end-stage cir-
rhosis in humans, using extrahepatic mesen-
Figure 3. Expression of α-SMA and collagen I proteins (A, B) and changes 
in mRNA levels (C) in the liver of CCl4 mice received hHSPC transplantation. 
(A, B) Upper panel: Immunoblots of four mice; lower panel: corresponding 
histograms of data of the blots. Both α-SMA and collagen I levels were re-
duced by nearly halves in the mice with the transplanted hHSPCs. Values are 
expressed as fold change relative to CCl4-treated mice; N = 4 mice/group. (C) 
While α-SMA, collagen α1(I) and TIMP-1 mRNA levels were downregulated, 
MMP-13 mRNA level was upregulated. The gene expression for TGF-β and 
MMP-2 was not altered. Values are expressed relative to CCl4-treated mice; 
N = 10 mice/group. 
human bone marrow were 
shown to diminish fibrosis and 
ameliorate chronic liver dam-
age in rats caused by CCl4 
[11]. Infusion of human bone 
marrow-derived mesenchymal 
stem cells led to an improve-
ment of CCl4-induced cirrhosis 
in mice [12]. The antifibrotic ef- 
fect was found to be associat-
ed with decreased expression 
of αSMA, TNF-α and TGF-β 
and conversely stimulation of 
MMP-9. Liver fibrosis can sp- 
ontaneously regress upon the 
cessation of fibrogenic agents. 
To that effect, transplantation 
of bone marrow cells facili-
tates the resolution of liver fi- 
brosis in mice, coincident with 
increased expression of the 
matrix protein degradation en- 
zymes MMP-13 and MMP-9 
[13]. The severity of cirrhosis 
caused by CCl4 in rats was 
lessened by infusion of human 
umbilical cord blood-derived 
mesenchymal cells, accompa-
nied by inhibition of TGF-β1, 
collagen I and α-SMA expres-
sion [14].
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chymal cells, or fetal and adult liver stem cells. 
In the present study, we sought to test the effi-
cacy of hHPSCs derived from adult human liver 
associated with downregulation of stellate cell 
activation phenotype, coincident with de- 
creased fibrogenic activity. Notably, the activity 
Figure 4. Expression of α-SMA and collagen I proteins (A, B) and changes in 
mRNA levels (C) in HSCs co-cultured with hHSPCs. (A, B) Upper panel: Immu-
noblots of three separate cultures; lower panel: corresponding histograms 
of data of the blots. Both α-SMA and collagen I levels in HSCs were reduced 
by halves in the presence of hHSPCs. Values are expressed relative to the 
control HEK293/HSC culture. (C) Control: HSCs were cultured alone in the 
bottom compartment of the Transwell, while the upper compartment con-
tained only the medium. Negative control: HSCs in the bottom compartment 
were co-cultured HEK293 cells in the upper compartment. hHSPC: HSCs 
were co-cultured with hHSPCs in the upper compartment. Gene expression 
for α-SMA, collagen α1(I) and TIMP-1 in HSCs were downregulated by the 
presence of hHSPCs. The mRNA level of MMP-1 was higher, while the levels 
of TGF-β and MMP-2 were not altered. Values are expressed relative to HSC 
control.
Figure 5. Effects of hHSPCs on proliferation of HSCs. Control: HSCs were 
cultured alone in the bottom compartment of the Transwell, while the up-
per compartment contained only the medium. Negative control: HSCs co-
cultured with HEK293 cells. hHSPCs: hHSPCs were co-cultured with HSCs. 
hHSPCs when co-cultured with HSCs at the ratio of 3/1 elicited a 25% inhibi-
tion of HSC proliferation. Values are expressed relative to HSC control.
in the prevention of advanced 
liver fibrosis development in 
CCl4-mice. Admittedly, our ex- 
perimental design is at vari-
ance with the protocols em- 
ploying cell therapy in the tre- 
atment of established cirrho-
sis in either animal models or 
patients in the clinical set-
tings. Nonetheless, our study 
discovered a novel action of 
hHSPCs against the histogen-
esis of liver fibrosis to ad- 
vanced stage fibrosis, namely 
bridging fibrosis and cirrhosis. 
The hHSPC’s antifibrotic ac- 
tion involves downregulation 
of HSC activation and modu- 
lation of expression of critical 
fibrogenic molecules that me- 
diate the production of colla-
gen I and hence fibrosis.  
HSCs residing in the space of 
Disse [19] produce the princi-
pal extracellular matrix pro-
teins in the liver, collagen I in- 
cluded [8]. HSCs express α- 
SMA, which is a phenotypic 
marker of human HSCs [20]. 
Additionally, HSCs synthesize 
MMP-1 (in humans) or MMP-
13 (in rodents), MMP-2, and 
TIMP-I in response to soluble 
signals released from profi-
brotic factors [21, 22]. Of th- 
ese genes, α-SMA, collagen I, 
MMP-2, TIMP-1 are upregulat-
ed during progressive liver fi- 
brosgenesis and in culture-in- 
duced activation of HSCs [22]. 
Therefore, expression of these 
transcripts is related to stel-
late cell activation. On the 
other hand, MMP-1 mRNA ex- 
pression, which is reduced in 
liver fibrosis, is enhanced in 
early primary HSC culture but 
then decreases in late culture. 
Thus, MMP-1 expression is 
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of MMP-1 is regulated by TIMP-1, its physiologi-
cal inhibitor. As a result, collagen deposition in 
liver fibrosis is the outcome of an imbalance 
between the production of MMP-1 and its inhib-
itor TIMP-1 [23]. 
Our study showed that transplantation of hHS- 
PCs prevents the development of advanced 
fibrosis (bridging fibrosis and cirrhosis) in CCl4-
mice. Instead, the liver of hHSPC-transplanted 
mice displays only occasional short septa and 
sporadic focal fibrotic tissue. The histopatho- 
logy was corroborated by histomorphometry, 
revealing a greater than 50% reduction in the 
amount of collagen deposition in the liver of 
CCl4-mice received the transplanted hHSPCs. 
Additionally, biochemical analysis disclosed 
that the hepatic α-SMA and collagen I proteins 
were significantly decreased with a correspond-
ing decrease in their gene expression. Con- 
comitantly, gene expression for α-SMA, colla-
gen α1(I), and TIMP-1 was suppressed while 
that of MMP-13 was enhanced. The downregu-
lation of α-SMA likely reflects the change in the 
activation of HSCs to a less activated state-or a 
more quiescent phenotype. Because MMP-1 is 
the major proteinase that degrades collagen I 
and its enzymatic activity is inhibited by TIMP-1, 
the imbalanced production of MMP-1 relative 
to TIMP-1 promotes the degradation of collagen 
I, thereby resulting in diminished collagen de- 
position. These changes could explain the de- 
crease in fibrosis in the liver with transplanted 
hHSPC in vivo. We also found that the trans-
planted hHSPCs are beneficial in correcting the 
liver damage caused by CCl4 treatment based 
on the decreased values of AST and ALT. 
We then tested whether hHSPCs interact with 
HSCs, promoting the downregulation of the fi- 
brogenic activities of HSCs. To that end, hHS- 
PCs were co-cultured with HSCs in a transwell 
system separated by a porous membrane filter. 
We found that α-SMA expression was lowered 
at both the protein and mRNA levels, indicat- 
ing the acquisition of a phenotype with a di- 
minished fibrogenic activity. Consequently, the 
levels collagen I mRNA level and protein were 
both decreased, coincident with increased ex- 
pression of MMP-1 while decreasing that of 
TIMP-1. The changes are consistent with find-
ings in vivo (vide supra) and provide an explana-
tion for the suppressed fibrogenesis at the cel-
lular level, i.e. HSCs.
TGF-β and MMP-2 are known to involve in the 
development of liver fibrosis [24]. However, our 
data did not show that the expression of these 
factors was altered under our experimental 
conditions, suggesting that their regulation is 
independent of the antifibrotic actions of hHS- 
PCs. Our study also showed that the prolifera-
tion of HSCs in coculture with hHSPCs is inhib-
ited although transiently. Because we did not 
determine HSC proliferation in vivo, the sig- 
nificance of inhibition of HSC proliferation by 
hHSPCs remains to be evaluated. 
In conclusion, we have isolated hHSPCs from 
adult human liver and characterized their stem/
progenitor cellular phenotypes. Our study docu-
mented the striking ability for transplanted 
hHSPCs to prevent the histogenesis of ad- 
vanced liver fibrosis in mice induced by CCl4. 
The antifibrotic action of hHSPCs in vivo ap- 
pears to involve downregulation of HSC activa-
tion and modulation of fibrogenic-related mole-
cule expression, and these effects in vivo were 
replicated in coculture comprising hHSPCs and 
human HSCs. Thus, our in vivo and in vitro cul-
ture findings together provide evidence for a 
functional link between hHSPCs and HSCs, 
which could explain the antifibrotic action of the 
transplanted hHSPCs. It is likely that hHSPCs 
secrete soluble molecules that modulate the 
fibrogenic activities of HSCs via a paracrine 
mechanism. It will be our continuous efforts to 
identify and characterize these paracrine fac-
tors released by hHSPCs. The current investiga-
tion is a new starting point for our goal to estab-
lish a preclinical model of adult hHSPC trans-
plantation for therapeutic intervention of the 
histogenesis of advanced hepatic fibrosis in 
humans. 
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